Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Leadership changes at Roche

<< Previous

Bullboard Posts

Next >>

Comment by Probosciseson Dec 12, 2022 2:32pm

187 Views

Post# 35166682

RE:Leadership changes at Roche

Pharma CEOs pay a price for failed strategies. Billion $ bets that go south are not looked upon kindly. After some notable and costly failures I thinks these Pharmas would be looking for largely de-risked winners, especially de-risked winners in lucrative and hard to treat cancers. As mentioned earlier these Pharmas also fear missing out on winners that then go to their competitors.

<< Previous

Bullboard Posts

Next >>

A guide to understanding technical analysis for small-cap stocks